Litcius/Paper detail

<scp>COVID</scp>‐19 in Parkinson’s Disease Patients Living in Lombardy, Italy

Alfonso Fasano, Emanuele Cereda, Michela Barichella, Erica Cassani, Valentina Ferri, Anna Zecchinelli, Gianni Pezzoli

2020Movement Disorders147 citationsDOIOpen Access PDF

Abstract

BACKGROUND: It is unknown whether patients with PD are at greater risk of COVID-19, what their risk factors are, and whether their clinical manifestations differ from the general population. OBJECTIVES: The study aimed to address all these issues. METHODS: In a case-controlled survey, we interviewed 1,486 PD patients attending a single tertiary center in Lombardy, Italy and 1,207 family members (controls). RESULTS: One hundred five (7.1%) and 92 controls (7.6%) were identified as COVID-19 cases. COVID-19 patients were younger, more likely to suffer from chronic obstructive pulmonary disease, to be obese, and vitamin D nonsupplemented than unaffected patients. Six patients (5.7%) and 7 family members (7.6%) died from COVID-19. Patients were less likely to report shortness of breath and require hospitalization. CONCLUSIONS: In an unselected large cohort of nonadvanced PD patients, COVID-19 risk and mortality did not differ from the general population, but symptoms appeared to be milder. The possible protective role of vitamin D supplementation warrants future studies. © 2020 International Parkinson and Movement Disorder Society.

Topics & Concepts

MedicineCoronavirus disease 2019 (COVID-19)CohortDiseasePediatricsPopulationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Cohort studyInternal medicineInfectious disease (medical specialty)Environmental healthVitamin D Research StudiesParkinson's Disease Mechanisms and TreatmentsLong-Term Effects of COVID-19